About GeneAssess, Inc.
GeneAssess, Inc. is, an early stage biotech company, founded in 2012. The company maintains office space at 120 Albany Street, New Brunswick, NJ 08901. Our current focus is dedicated to the discovery, development, and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for cancer patients.
We are developing new diagnostic and genetic tests for assessing cancer risk based on the expression and the DNA sequence of the FRY, a putative tumor suppressor gene and a novel cancer biomarker. In addition, we intend to develop mechanistically-based, percision cancer therapies using FRY signal targeting methodology.